These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 23117849)
1. Clinical outcome after a totally implantable venous access port-related infection in cancer patients: a prospective study and review of the literature. Lebeaux D; Larroque B; Gellen-Dautremer J; Leflon-Guibout V; Dreyer C; Bialek S; Froissart A; Hentic O; Tessier C; Ruimy R; Pelletier AL; Crestani B; Fournier M; Papo T; Barry B; Zarrouk V; Fantin B Medicine (Baltimore); 2012 Nov; 91(6):309-318. PubMed ID: 23117849 [TBL] [Abstract][Full Text] [Related]
2. Outcome of totally implantable venous-access port-related infections. Vidal M; Genillon JP; Forestier E; Trouiller S; Pereira B; Mrozek N; Aumeran C; Lesens O Med Mal Infect; 2016 Feb; 46(1):32-8. PubMed ID: 26778362 [TBL] [Abstract][Full Text] [Related]
3. Late complications associated with totally implantable venous access port implantation via the internal jugular vein. Tsuruta S; Goto Y; Miyake H; Nagai H; Yoshioka Y; Yuasa N; Takamizawa J Support Care Cancer; 2020 Jun; 28(6):2761-2768. PubMed ID: 31724073 [TBL] [Abstract][Full Text] [Related]
4. TIVAP-related infection due to Gram-negative aerobic bacilli: should TIVAP stay or should it go? Rolland S; Kassis-Chikhani N; Auclin E; Bensaid S; Bidaud AL; Gerlinger MP; Blez D; Mainardi JL; Lebeaux D; Dubert M Eur J Clin Microbiol Infect Dis; 2023 Feb; 42(2):161-168. PubMed ID: 36472717 [TBL] [Abstract][Full Text] [Related]
5. Risk factors and prognostic significance of infection of totally implantable vascular access port in solid tumor patients: A prospective cohort study. Bailleul A; Fulgencio JP; Vimont S; Mordelet C; Ray B; Lassel L; Lapidus N; Quesnel C; Garnier M Infect Dis Now; 2023 Oct; 53(8):104766. PubMed ID: 37543258 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of vancomycin lock therapy for totally implantable venous access port-related infection due to coagulase-negative staphylococci in 100 patients with cancer. Lafaurie M; Montlahuc C; Kerneis S; de Lastours V; Abgrall S; Manceron V; Couzigou C; Chabrol A; de Raigniac A; Lescure X; Longuet P; Lesprit P; Vanjak D; Lepeule R; J Antimicrob Chemother; 2023 May; 78(5):1253-1258. PubMed ID: 37014800 [TBL] [Abstract][Full Text] [Related]
7. Infections Related to Totally Implantable Venous-Access Ports: Long-Term Experience in One Center. Ji L; Yang J; Miao J; Shao Q; Cao Y; Li H Cell Biochem Biophys; 2015 May; 72(1):235-40. PubMed ID: 25542370 [TBL] [Abstract][Full Text] [Related]
8. Taurolidine/Citrate Lock Therapy for Primary Prevention of Catheter-Related Infections in Cancer Patients: Results of a Prospective, Randomized, Phase IV Trial (ATAPAC). Longo R; Llorens M; Goetz C; Platini C; Eid N; Sellies J; Ouamara N; Quétin P Oncology; 2017; 93(2):99-105. PubMed ID: 28463827 [TBL] [Abstract][Full Text] [Related]
9. Infection of totally implantable venous access devices: A review of the literature. Pinelli F; Cecero E; Degl'Innocenti D; Selmi V; Giua R; Villa G; Chelazzi C; Romagnoli S; Pittiruti M J Vasc Access; 2018 May; 19(3):230-242. PubMed ID: 29512430 [TBL] [Abstract][Full Text] [Related]
10. Risk factors for central line-associated bloodstream infection in pediatric oncology patients with a totally implantable venous access port: A cohort study. Viana Taveira MR; Lima LS; de Araújo CC; de Mello MJ Pediatr Blood Cancer; 2017 Feb; 64(2):336-342. PubMed ID: 27666952 [TBL] [Abstract][Full Text] [Related]
11. Incidence of and mortality due to sepsis, severe sepsis and septic shock in Italian Pediatric Intensive Care Units: a prospective national survey. Wolfler A; Silvani P; Musicco M; Antonelli M; Salvo I; Intensive Care Med; 2008 Sep; 34(9):1690-7. PubMed ID: 18500425 [TBL] [Abstract][Full Text] [Related]
12. Silver-Mixed Port Reduces Venous Access Port Related Infection Rate Compared to Non-Silver-mixed Port: A Single-center Retrospective Analysis. Suzuki T; Michimoto K; Hasumi J; Kisaki S; Hasegawa Y; Fujimori A; Yoshimatsu L; Ashida H; Ojiri H Cardiovasc Intervent Radiol; 2023 Dec; 46(12):1696-1702. PubMed ID: 37902854 [TBL] [Abstract][Full Text] [Related]
13. Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device. Biffi R; Corrado F; de Braud F; de Lucia F; Scarpa D; Testori A; Orsi F; Bellomi M; Mauri S; Aapro M; Andreoni B Eur J Cancer; 1997 Jul; 33(8):1190-4. PubMed ID: 9301441 [TBL] [Abstract][Full Text] [Related]
14. [Totally implantable venous access ports: frequency of complications and analysis of bacterial contamination after ablation]. Barbut F; Soukouna S; Lalande V; Garcia ML; Neyme D; de Gramont A; Petit JC Pathol Biol (Paris); 2004 Dec; 52(10):566-74. PubMed ID: 15596304 [TBL] [Abstract][Full Text] [Related]
15. Comparison of methods for the microbiological diagnosis of totally implantable venous access port-related infections. Kaya E; Tollapi L; Pastore A; Aringhieri G; Maisetta G; Barnini S; Paolicchi A; Batoni G; Esin S J Med Microbiol; 2020 Nov; 69(11):1273-1284. PubMed ID: 33064069 [No Abstract] [Full Text] [Related]
16. Risk factors for central venous catheter-related bloodstream infections after gastrointestinal surgery. Wu S; Ren S; Zhao H; Jin H; Xv L; Qian S; Wang S Am J Infect Control; 2017 May; 45(5):549-550. PubMed ID: 28233571 [TBL] [Abstract][Full Text] [Related]
17. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Biffi R; de Braud F; Orsi F; Pozzi S; Mauri S; Goldhirsch A; Nolè F; Andreoni B Ann Oncol; 1998 Jul; 9(7):767-73. PubMed ID: 9739444 [TBL] [Abstract][Full Text] [Related]
18. Incidence and risk factor for infection of totally implantable venous access port. Chang TC; Yen MH; Kiu KT Langenbecks Arch Surg; 2022 Feb; 407(1):343-351. PubMed ID: 34550464 [TBL] [Abstract][Full Text] [Related]
19. [Incidence, prevalence and risk factors for a first infectious complication on a totally implantable venous-access port]. Crisinel M; Mahy S; Ortega-Debalon P; Buisson M; Favre JP; Chavanet P; Piroth L Med Mal Infect; 2009 Apr; 39(4):252-8. PubMed ID: 19108966 [TBL] [Abstract][Full Text] [Related]
20. Clinical impact of peripherally inserted central catheters vs implanted port catheters in patients with cancer: an open-label, randomised, two-centre trial. Taxbro K; Hammarskjöld F; Thelin B; Lewin F; Hagman H; Hanberger H; Berg S Br J Anaesth; 2019 Jun; 122(6):734-741. PubMed ID: 31005243 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]